TopFunds

Charles River Laboratories

NYSE: CRL

Stock price

298 USD

(+0%) TODAY

Life Sciences Tools & ServicesMedical - Diagnostics & Research
Financials

all figures in US$ Millions except per share data

Sections:

Periods:

View:

Format:

Actual
10 year cagr
Help
Where available up to 10y CAGR shown for absolute numbers 10y Average marked A shown for relative numbers such as margins
Fiscal
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Average (A)
Fiscal period end dates
Expand all rows
01Earnings per share
Help
Earnings per share = Net Income / Number of Shares Outstanding
3.1
3.2
2.5
4.6
5.1
7.2
7.6
9.5
9.2
0.2
(2.9)
-
02Free cash flow per share
4.7
5.1
4.8
6.1
6.9
7.5
10.3
5.7
7.1
9.7
10.5
8.4%
03Dividends per share
-
-
-
-
-
-
-
-
-
-
-
-
04Dividends payout, %
-
-
-
-
-
-
-
-
-
-
-
-
PROFIT AND LOSS STATEMENT
05Revenue
1,363
1,681
1,858
2,266
2,621
2,924
3,540
3,976
4,129
4,050
4,015
11.4%
06% Change
-
-
-
-
-
-
-
-
-
-
-
11.4%
07Cost of revenue
(832.2)
(1,038)
(1,157)
(1,426)
(1,663)
(1,850)
(2,206)
(2,513)
(2,627)
(2,718)
(2,790)
12.9%
08Gross profit
531.1
644
700.9
840.1
958.3
1,074
1,335
1,463
1,503
1,332
1,226
8.7%
09% Margin
39%
38.3%
37.7%
37.1%
36.6%
36.7%
37.7%
36.8%
36.4%
32.9%
30.5%
36.3% A
10Operating expenses
(324.6)
(406.4)
(412.6)
(508.7)
(607.2)
(640.8)
(744.8)
(811.7)
(885.3)
(1,105)
(717.7)
8.3%
11% of Revenue
(23.8)%
(24.2)%
(22.2)%
(22.5)%
(23.2)%
(21.9)%
(21)%
(20.4)%
(21.4)%
(27.3)%
(17.9)%
(22.3)% A
12Operating Income
206.4
237.6
288.3
331.4
351.2
432.7
589.9
651
617.3
227.3
507.8
9.4%
13Income tax expense
(43.4)
(66.8)
(171.4)
(54.5)
(50)
(81.8)
(81.9)
(130.4)
(100.9)
(67.8)
(42.7)
(0.2)%
14Net Income
149.3
154.8
123.4
226.4
252
364.3
391
486.2
474.6
10.3
(144.3)
-
15% Margin
11%
9.2%
6.6%
10%
9.6%
12.5%
11%
12.2%
11.5%
0.3%
(3.6)%
8.2% A
16Shares Outstanding
47.6
48
48.6
49
49.7
50.6
51.4
51.3
51.5
51.6
49.6
0.4%
17EPS Basic
3.2
3.3
2.6
4.7
5.2
7.4
7.8
9.6
9.3
0.2
(2.9)
-
18EPS Diluted
3.1
3.2
2.5
4.6
5.1
7.2
7.6
9.5
9.2
0.2
(2.9)
-
19EBITDA
305.4
377.3
457.9
507.2
563.1
768.5
820.2
986.1
1,032
581.1
410.8
3%
% Margin
22.4%
22.4%
24.7%
22.4%
21.5%
26.3%
23.2%
24.8%
25%
14.4%
10.2%
21.6% A
20Net Interest Income (expense)
(14)
(26.4)
(29.1)
(63)
(59.4)
(85.6)
(73.3)
(58.5)
(131.5)
(117.7)
(102.1)
22%
21Net Debt / EBITDA
2.4
3
2.1
3
3.2
2.5
3.6
2.9
2.7
4.4
6.9
3.3 A
BALANCE SHEET
ASSETS
Current Assets
22Cash & equivalents
117.9
117.6
163.8
195.4
238
228.4
245.2
233.9
276.8
194.6
213.8
6.1%
23Short-term investments
-
-
-
-
0.9
1
-
-
-
-
-
8.8%
24Accounts receivable
270.1
364.1
430
472.2
514
617.7
650.4
752.4
780.4
720.9
708.9
10.1%
25Other current assets
56.7
75
88.8
100.9
107.7
168.2
178.3
196.9
171.3
209
224.7
14.8%
26Inventory
93.7
95.8
115
127.9
160.7
185.7
199.1
255.8
380.3
278.5
299.1
12.3%
27Total Current Assets
559.2
656.8
826.6
897.8
1,021
1,201
1,274
1,439
1,609
1,403
1,447
10%
Non-Current Assets
28Net property, plant & equipment
678
755.8
782
932.9
1,184
1,303
1,584
1,857
2,034
2,017
2,017
11.5%
29Long-term investments
32.7
45.3
71.1
88.6
123
221.8
201.4
311.6
243.8
218.4
207
20.3%
30Other non-current assets
798.6
1,254
1,250
1,937
2,364
2,765
3,965
3,995
4,309
3,890
3,465
15.8%
31Total Non-Current Assets
1,509
2,055
2,103
2,958
3,672
4,290
5,750
6,164
6,586
6,125
5,688
14.2%
Total Assets
2,069
2,712
2,930
3,856
4,693
5,491
7,024
7,603
8,195
7,528
7,135
13.2%
LIABILITIES
Current Liabilities
32Accounts payable
36.7
68.5
77.8
66.3
111.5
122.5
198.1
205.9
168.9
140.3
148.8
15%
33Short-term debt
17
27.3
31
34.6
58.9
74.9
36.1
-
-
-
61.1
13.6%
34Other current liabilities
258.1
333.8
354.7
457.4
539.8
642.4
799
885.7
886.1
853.8
910.5
13.4%
35Total Current Liabilities
311.8
429.6
463.5
558.2
710.2
839.8
1,033
1,092
1,055
994.1
1,120
13.7%
Non-Current Liabilities
36Long-term debt
877.8
1,235
1,142
1,663
1,966
2,085
3,170
3,097
3,066
2,724
3,005
13.1%
37Other non-current liabilities
113.4
193.5
260.4
296.7
350.2
422.2
229.6
390.4
414.5
302.2
(200.5)
-
38Total Non-Current Liabilities
991.2
1,428
1,402
1,959
2,316
2,507
3,399
3,488
3,481
3,026
2,804
11%
39Total Liabilities
1,303
1,858
1,866
2,518
3,026
3,347
4,432
4,579
4,536
4,020
3,924
11.7%
SHAREHOLDERS` EQUITY
40Common stock
0.9
0.9
0.9
0.5
0.5
0.5
0.5
0.5
0.5
0.5
0.5
(5.4)%
41Retained earnings / (deficit)
10.5
165.3
288.7
42.1
280.3
625.4
980.8
1,433
1,887
1,812
1,389
62.9%
42Accumulated other comprehensive income / (loss)
(135.5)
(253.8)
(144.7)
(172.7)
(178)
(138.9)
(164.7)
(262.1)
(196.4)
(317.3)
(171.8)
2.4%
43Noncontrolling interests
32.5
17
18.9
21
31.9
29.1
57.2
47.2
62.1
46.6
46.6
3.7%
44Total shareholders' equity
765.6
853.8
1,064
1,338
1,667
2,144
2,592
3,024
3,659
3,508
3,211
15.4%
45Total Liabilities and shareholders' Equity
2,069
2,712
2,930
3,856
4,693
5,491
7,024
7,603
8,195
7,528
7,135
13.2%
46Total Debt
863
1,235
1,145
1,697
2,025
2,160
3,206
3,097
3,066
2,724
3,066
13.5%
47Net Debt
745.1
1,117
981.3
1,502
1,787
1,932
2,964
2,863
2,790
2,529
2,852
14.4%
CASH FLOW STATEMENT
CASH FLOWS FROM OPERATING ACTIVITIES
48Net income (loss)
149.3
154.8
123.4
226.4
252
364.3
391
486.2
474.6
10.3
(144.3)
-
49Depreciation & amortization
94.9
126.7
131.2
161.8
198.1
234.9
265.5
303.9
314.1
361.7
403.3
15.6%
50Share-based compensation expense
40.1
43.6
44
47.3
57.3
56.3
71.5
73.6
72
69.9
71.1
5.9%
51Changes in working capital and other assets
2
(26.7)
17.7
5.6
(26.4)
(109)
32.8
(244.1)
(176.9)
292.6
407.6
69.8%
52Net cash flows from operating activities
286.4
298.3
316.3
441.1
480.9
546.6
760.8
619.6
683.9
734.6
737.6
9.9%
CASH FLOWS FROM INVESTING ACTIVITIES
53Purchases of property, plant and equipment
(63.3)
(55.3)
(82.4)
(140.1)
(140.5)
(166.6)
(228.8)
(324.7)
(318.5)
(233)
(219.2)
13.2%
54Purchases of investments / marketable securities
(34.2)
(40.2)
(46.2)
(25.1)
(22.3)
(26.7)
(45.6)
(158.3)
(54.2)
(52.9)
(20.1)
(5.2)%
55Proceeds from maturities of marketable securities
27.1
54
9.1
35.8
0.9
11.4
6.5
4.5
6.7
41.7
9.1
(10.3)%
56Other investing activities
(249.9)
(644.8)
46.9
(825.7)
(519.6)
(419.7)
(1,170)
(129.5)
(197.1)
(0.9)
20.8
-
57Net cash flows from investing activities
(320.3)
(686.4)
(72.6)
(955)
(681.5)
(601.5)
(1,438)
(607.9)
(563.2)
(245.1)
(209.3)
(4.2)%
CASH FLOWS FROM FINANCING ACTIVITIES
58Issuance (repurchases) of common stock, net
(117.5)
(12.3)
(106.9)
(13.8)
(18.1)
(24)
(40.7)
(38.7)
(24.2)
(119.2)
(360)
11.9%
59Dividends paid, net
-
-
-
-
-
-
-
-
-
-
-
-
60Debt issuance (repayments), net
75.2
388
(135.6)
554
233.9
30.6
670
19.8
(75.3)
(412.2)
(121.8)
-
61Other financing activities
46.8
15
34
17.9
16.2
40.6
43.3
(23.5)
14
(19.6)
(55)
-
62Net cash flows from financing activities
4.5
390.7
(208.5)
558.1
231.9
47.2
672.6
(42.4)
(85.5)
(550.9)
(536.7)
-
63Increase (decrease) in cash and cash equivalents
(42.1)
(0.3)
46.4
31
42.7
(6.9)
13.2
(5.1)
43.3
(78.9)
10.4
-
64Cash and equivalents, ending balance
117.9
117.6
166.3
197.3
240
233.1
246.3
241.2
284.5
205.6
216
6.2%
65Free Cash Flow to the Firm (FCFF)
Help
Free Cash Flow to the Firm = Cash Flows from Operating Activities - Capital Expenditures
223.1
243
233.8
301.1
340.4
380
532
294.9
365.4
501.6
518.5
8.8%

Annual Reports, Presentations And IR Contacts

Go to the website
Annual report links (10K)
2025202420232022202120202019201820172016

Charles River Laboratories (CRL) financial statements and performance

Explore Charles River Laboratories (CRL) annual and quarterly financial statements, including revenue, operating income, net income, cash flow, assets, liabilities, and per-share metrics.

Compare reporting periods and financial trends to evaluate profitability, balance-sheet strength, cash generation, and long-term business performance.